Evidence map›Paper›PMID 36590993›Full record

ArticleThe Pan African medical journal2022

Seroprevalence of hepatitis C virus antigen in patients with chronic liver disease and hepatocellular carcinoma at 12

Donatien Serge Mbaga, Jacky Njiki Bikoï, Etienne Atenguena Okobalemba, Justin Olivier Essindi, Chris André Mbongue Mikangue, Alexandra Emmanuelle Membangbi, Aïcha Ngoutane, Arnaud Franck Elang, Sabine Aimée Touangnou-Chamda, Carole Stéphanie Sake and 3 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in The Pan African medical journal, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Donatien Serge MbagaDepartment of Microbiology, The University of Yaoundé I, Yaoundé, Cameroon.
Jacky Njiki BikoïDepartment of Microbiology, The University of Yaoundé I, Yaoundé, Cameroon.
Etienne Atenguena OkobalembaFaculty of Medicine and Biomedical Sciences, The University of Yaoundé I, Yaoundé, Cameroon.
Justin Olivier EssindiDepartment of Microbiology, The University of Yaoundé I, Yaoundé, Cameroon.
Chris André Mbongue MikangueDepartment of Microbiology, The University of Yaoundé I, Yaoundé, Cameroon.
Alexandra Emmanuelle MembangbiDepartment of Microbiology, The University of Yaoundé I, Yaoundé, Cameroon.
Aïcha NgoutaneDepartment of Microbiology, The University of Yaoundé I, Yaoundé, Cameroon.
Arnaud Franck ElangDepartment of Microbiology, The University of Yaoundé I, Yaoundé, Cameroon.
Sabine Aimée Touangnou-ChamdaDepartment of Microbiology, The University of Yaoundé I, Yaoundé, Cameroon.
Carole Stéphanie SakeDepartment of Microbiology, The University of Yaoundé I, Yaoundé, Cameroon.
George Ikomey MondindeFaculty of Medicine and Biomedical Sciences, The University of Yaoundé I (Center for the Study and Control of Communicable Diseases (CSCCD), Yaoundé, Cameroon.
Sebastien KenmoeDepartment of Microbiology and Parasitology, University of Buea, Buea, Cameroon.
Sara Honorine Riwom EssamaDepartment of Microbiology, The University of Yaoundé I, Yaoundé, Cameroon.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: epidemiological data suggests that more than 50% of hepatitis C virus (HCV) patients fail treatment. The objective of the study was to highlight the seroprevalence of hepatitis C virus antigen (HCV Ag) at the 12 Methods: during a cross-sectional study, participants with chronic liver disease and hepatocellular carcinoma (HCC) were recruited between December 2020 and March 2022 at the Yaoundé General Hospital (HGY) and the University Teaching Hospital of Yaounde (UTHY). Five millilitres of blood samples were taken from each consenting participant and then a qualitative search for HCV Ag by Enzyme-Linked Immuno Assay (ELISA) was performed. Analysis of the results was performed using SPSS Version 25.0 software. Results: out of the 192 participants selected for the study, only 92 (47,9%) participants were at 12 weeks of treatment, including 69 (75%) participants positive for the hepatitis C virus antibody (HCV Ab) by RDT. Of these participants, 44 (47.8%) participants were positive for HCV Ag by ELISA, respectively 19/37 (51.3%), 14/19 (73.6%), 11/13 (84.6%) with chronic hepatitis (HC), Cirrhosis, and HCC (P<0.0001). Conclusion: our results showed a high prevalence of HCV Ag in patients at their 12

Indexed as

Carcinoma, HepatocellularHepatitis CHepatitis C, ChronicLiver NeoplasmsCameroonCross-Sectional StudiesHepacivirusHepatitis C AntibodiesHumansLiver CirrhosisSeroepidemiologic StudiesHepatitis C Antibodieschronic hepatitiscirrhosisHepatitis C virus Aghepatocellular carcinoma

Identifiers

PMID36590993
PMCPMC9789782

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.